You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: 10,258,564


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,258,564 protect, and when does it expire?

Patent 10,258,564 protects ZELSUVMI and is included in one NDA.

This patent has sixteen patent family members in seven countries.

Summary for Patent: 10,258,564
Title:Topical compositions and methods of using the same
Abstract:The present invention relates generally to compositions and methods of using the same. A first aspect of the present invention comprises a composition comprising a first viscosity increasing agent; at least one polyhydric alcohol; at least one buffering agent; at least one preservative; a second viscosity increasing agent; at least one organic solvent; at least one humectant; at least one active pharmaceutical ingredient; and water, wherein the composition is buffered to a pH of about 3 to about 11.
Inventor(s):Doxey Ryan, Sabouni Adam, Kougoulos Eleftherios, Stasko Nathan
Assignee:Novan, Inc.
Application Number:US14771138
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 10,258,564

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lnhc ZELSUVMI berdazimer sodium GEL;TOPICAL 217424-001 Jan 5, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS ⤷  Sign Up
Lnhc ZELSUVMI berdazimer sodium GEL;TOPICAL 217424-001 Jan 5, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES A NITRIC OXIDE RELEASING COMPOUND ⤷  Sign Up
Lnhc ZELSUVMI berdazimer sodium GEL;TOPICAL 217424-001 Jan 5, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES WATER ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,258,564

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014223164 ⤷  Sign Up
Brazil 112015019657 ⤷  Sign Up
Canada 2900557 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.